Effect of Intravenous Zoledronic Acid on Bone Mineral Density in Osteoporosis Patients

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003045

Enrollment

Registered

2018-07-31

Start date

2018-04-16

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : This study is conducted on 50 patients diagnosed with osteoporosis according to the criteria of the World Health Organization (WHO) age 50 or older. Patients who agreed to participate in the st

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Adults over 50 years old. ? diagnosed as osteoporosis (T-score = 2.5).

Exclusion criteria

Exclusion criteria: ? Creatinin clearance rate < 35mL/min ? Hypersensitivity in Bisphosphonates ? Hypersensitivity of Zoledronic acid ? Serum calcium concentration = 8.4mg/dL ? Pretnant or breast feeding

Design outcomes

Primary

Measure	Time frame
Bone mineral density (BMD) (dual energy X-ray absorptiometry) is used for the diagnosis of osteoporosis in patients over 50 years of age. After intravenous injection of 5 mg of zoledronic acid, the side effects, type and severity are assessed. At the end of the first year, the effect of the zoledronic acid injection is evaluated by re-evaluating the BMD.	—

Secondary

Measure	Time frame
Laboratory test (osteocalcin, c-telopeptide, vitamin D, calcium) are evaluated before and one year after the administration of zoledronic acid.	—

Countries

Korea, Republic of

Contacts

Public ContactMin Cheol Joo

Wonkwang University Hospital

jmc77@daum.net+82-63-859-1612

Outcome results